Literature DB >> 3129867

Differentiation of plasma cell infiltrates in the bone marrow. A clinicopathological study on 80 patients including immunohistochemistry and morphometry.

J Thiele1, B Arenz, H Klein, M Vierbuchen, R Zankovich, R Fischer.   

Abstract

In 80 patients immunohistochemical, morphometrical and clinical studies were performed on routinely referred trephine biopsies of the bone marrow showing an abnormal increase in plasma cells. From the approximately determined density of plasma cell infiltrates two main groups were distinguished, the first with an involvement exceeding 20% and the second with less than 10% of the total marrow area involved. The first group (n = 30; 324 +/- 130 plasma cells per square millimeter bone marrow) consisted of patients with frank malignant myeloma (MM) by clinical and histomorphological diagnosis. The second group (n = 50; 132 +/- 54 plasma cells per square millimeter bone marrow) with plasmacytic differentiation of infiltrates, had to be further divided into one component with evidence for initial or residual MM following chemotherapy (n = 27), another with obviously monoclonal gammopathy of undetermined significance--benign monoclonal gammopathy (BMG, n = 6), and a final set of cases with a reactive plasmacytosis mostly associated with an inflammatory condition (n = 17). There was an excellent agreement between the intracellular immunoglobulin staining as defined by the immunoperoxidase technique and the serum or urinary M-component detected by immunoelectrophoresis. In MM significant correlations were found between osteoclastic activity (number of osteoclasts specifically stained by acid phosphatase) per trabecular bone area, presence of lytic bone defects and the density of plasma cell infiltrates in the marrow. This latter feature corresponded well with the titer of secreted serum M-components measured by quantitative immunoelectrophoresis. Using morphological data alone, BMG cases could not be discriminated with any certainty from initial or residual plasmacytic MM. They consequently need a prolonged clinical follow up to clarify the nature of the lesions.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3129867     DOI: 10.1007/bf00844291

Source DB:  PubMed          Journal:  Virchows Arch A Pathol Anat Histopathol        ISSN: 0174-7398


  29 in total

1.  Idiopathic (asymptomatic) monoclonal gammopathies.

Authors:  S E Ritzmann; D Loukas; H Sakai; J C Daniels; W C Levin
Journal:  Arch Intern Med       Date:  1975-01

2.  Multiple myeloma or benign monoclonal gammopathy? A study of differential diagnostic criteria in 44 cases.

Authors:  F D Lindström; U Dahlström
Journal:  Clin Immunol Immunopathol       Date:  1978-06

3.  The use of proteolytic enzymes to improve immunoglobulin staining by the PAP technique.

Authors:  B L Mepham; W Frater; B S Mitchell
Journal:  Histochem J       Date:  1979-05

4.  Bone resorbing activity in supernatant fluid from cultured human peripheral blood leukocytes.

Authors:  J E Horton; L G Raisz; H A Simmons; J J Oppenheim; S E Mergenhagen
Journal:  Science       Date:  1972-09-01       Impact factor: 47.728

5.  Bone marrow biopsy with unaltered architecture: a new biopsy device.

Authors:  K Jamshidi; W R Swaim
Journal:  J Lab Clin Med       Date:  1971-02

6.  Partial purification of osteoclast-activating factor from phytohemagglutinin-stimulated human leukocytes.

Authors:  R A Luben; G R Mundy; C L Trummel; L G Raisz
Journal:  J Clin Invest       Date:  1974-05       Impact factor: 14.808

7.  Distribution of IgA1 and IgA2 subclasses in normal bone marrow trephines and in trephines infiltrated by IgA producing multiple myeloma.

Authors:  P Lenormand; J Crocker
Journal:  J Clin Pathol       Date:  1987-02       Impact factor: 3.411

8.  Specific identification of intracellular immunoglobulin in paraffin sections of multiple myeloma and macroglobulinemia using an immunoperoxidase technique.

Authors:  G S Pinkus; J W Said
Journal:  Am J Pathol       Date:  1977-04       Impact factor: 4.307

9.  Immunoperoxidase staining of bone marrow sections.

Authors:  J L Hitzman; C Y Li; R A Kyle
Journal:  Cancer       Date:  1981-12-01       Impact factor: 6.860

10.  Relation of osteoclast activating factor production to extent of bone disease in multiple myeloma.

Authors:  B G Durie; S E Salmon; G R Mundy
Journal:  Br J Haematol       Date:  1981-01       Impact factor: 6.998

View more
  3 in total

1.  Bone marrow trephine biopsy in lymphoproliferative disease.

Authors:  C Schmid; P G Isaacson
Journal:  J Clin Pathol       Date:  1992-09       Impact factor: 3.411

2.  Assessment of bone marrow plasma cell infiltrates in multiple myeloma: the added value of CD138 immunohistochemistry.

Authors:  Samer Z Al-Quran; Lijun Yang; James M Magill; Raul C Braylan; Vonda K Douglas-Nikitin
Journal:  Hum Pathol       Date:  2007-08-21       Impact factor: 3.466

3.  Focal lymphoid aggregates (nodules) in bone marrow biopsies: differentiation between benign hyperplasia and malignant lymphoma--a practical guideline.

Authors:  J Thiele; T K Zirbes; H M Kvasnicka; R Fischer
Journal:  J Clin Pathol       Date:  1999-04       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.